Skip to content

Vitamin D supplementation and obesity

Effect of vitamin D supplementation on anthropometric indices and lipid profile among overweight and obese women : A Placebo-controlled Randomized Clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013072814195N1
Enrollment
76
Registered
2013-09-05
Start date
2013-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: obesity. Condition 2: overweight. Obesity due to excess calories Obesity, unspecified

Interventions

Intervention 1: Patients in the control group receive oral placebo which are specifically designed to have no real effect. They are made of lactose.These pearls in terms of size, shape, packaging an
Treatment - Drugs
Patients in the control group receive oral placebo which are specifically designed to have no real effect. They are made of lactose.These pearls in terms of size, shape, packaging and name are exact
Oral vitamin D supplement ( pearl ) 2000 IU/ d ( = 50 µg/d as cholecalciferol ) will be given to the intervention group until 3 months. Each pearl contains 50000 IU vitamin D3. One pearl will be given

Sponsors

Vice chancellor for research Lorestan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age of 18-70 and BMI>25 Exclusion criteria: to have history of vitamin D deficiency,diabetes mellitus,thyroid disorders, hyperlipidemia,cardiac diseases and use of vitamins and mineral supplements.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Body Mass Index (BMI). Timepoint: before intervention and 3 months after study. Method of measurement: balance-meter.;Waist to Hip ratio (W/H). Timepoint: before intervention and 3 months after study. Method of measurement: meter.

Secondary

MeasureTime frame
Total cholesterol. Timepoint: before intervention and 3 months after study. Method of measurement: spectrophotometer.;Triglyceride. Timepoint: before intervention and 3 months after study. Method of measurement: spectrophotometer.;Low density lipoprotein ( LDL). Timepoint: Before intervention and 3 months after study. Method of measurement: Spectrophotometer.;High density lipoprotein (HDL). Timepoint: before intervention and 3 months after study. Method of measurement: spectrophotometer.;Serum 25 hydroxyvitamin D. Timepoint: Before intervention and 3 months after study. Method of measurement: IBL company laboratory kit.;Serum calcium. Timepoint: Before intervention and 3 months after study. Method of measurement: Spectrophotometer.;Serum phosphorus. Timepoint: Before intervention and 3 months after study. Method of measurement: spectrophotometer.;Parathyroid hormone (PTH). Timepoint: Before intervention and 3 months after study. Method of measurement: ELISA.;Received energy. Timepoint: 3 days during the intervention. Method of measurement: Questionnaire and N4 software.;Received calcium. Timepoint: 3 days during the intervention. Method of measurement: Questionnaire and N4 software.;Received phosphorus. Timepoint: 3 days during the intervention. Method of measurement: Questionnaire and N4 software.;Received vitamin D. Timepoint: 3 days during the intervention. Method of measurement: Questionnaire and N4 software.;Received nutrient elements. Timepoint: 3 days during the intervention. Method of measurement: Questionnaire and N4 software.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hasan Kayedi

Vice chancellor for research and technology of Lorestan University Of Medical Sciences

kayedi@lums.ac.ir+98 66 1331 0771

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026